case_images: PMC10437098_01
case_images: Skin lesion performance of abrocitinib before and after treatment of patients with EPPP. (a) Skin lesions prior to the treatment; (b) Lesion at higher magnification; (c) Significant improvement in the degree of skin lesions after one month of treatment with abrocitinib.
case_images: CCID-16-2223-g0001.jpg
case_images: PMC10437098_01_CCID-16-2223-g0001.jpg
case_images: f0001
case_images: These papules exhibited old central atrophy, and they were well-defined, slightly raised, and partially covered with thin scales (Figures 1a and b). After 1-month oral administration of abrocitinib, the skin lesions gradually subsided (Figure 1c).
case_images: Pathological presentation of the patient. (HE, x100). The epidermis is mildly hyperplastic, with several keratin-filled depressions showing a tendency to form a conical plate with vacuolated epithelial cells and a partial lack of a granular layer. Lymphocyte infiltration can be seen around dermal vessels (a and b).
case_images: CCID-16-2223-g0002.jpg
case_images: PMC10437098_01_CCID-16-2223-g0002.jpg
case_images: f0002
case_images: Moreover, lymphocyte infiltration was observed around dermal vessels (Figures 2a and b).
case_images: Questionnaire evaluation of abrocitinib before and after treating patients with EPPP. Pruritus was assessed using the visual analog scale (VAS) and the 12-item pruritus severity scale (12-PSS), and data on quality of life were assessed using the dermal life quality index (DLQI).
case_images: CCID-16-2223-g0003.jpg
case_images: PMC10437098_01_CCID-16-2223-g0003.jpg
case_images: f0003
case_images: The subsequent VAS, 12-PSS, and DLQI scores of the patient decreased to 2, 3, and 4, respectively (Figure 3).